8-KLeadership ChangesRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (May 21, 2024)

Filed May 21, 2024For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) announced the appointment of Robert B. Carter to its Board of Directors, effective May 16, 2024. Mr. Carter brings significant executive experience, currently serving as Executive Vice President and Chief Information Officer at FedEx Corporation, and Co-President and Co-CEO of FedEx Services. His addition to the Board is expected to enhance the company's strategic oversight and digital transformation efforts, given his extensive background in technology and corporate leadership. The Board has determined that Mr. Carter meets the independence criteria set forth by the New York Stock Exchange and the Company's own governance guidelines. His appointment as a non-employee director means he will be compensated according to the company's standard practices for its non-employee directors. Further details regarding committee assignments are pending.

Key Highlights

  • 1Robert B. Carter elected to the Board of Directors as an independent director, effective May 16, 2024.
  • 2Mr. Carter's current role is Executive Vice President, Chief Information Officer of FedEx Corporation.
  • 3Mr. Carter also holds the titles of Co-President and Co-CEO of FedEx Services.
  • 4The Board has confirmed Mr. Carter's independence according to NYSE and company guidelines.
  • 5Mr. Carter will receive standard compensation for non-employee directors.
  • 6The press release announcing this appointment is attached as Exhibit 99.1.

Frequently Asked Questions

Robert B. Carter is a new independent director appointed to Quest Diagnostics' Board of Directors. He brings extensive executive experience, notably as the Chief Information Officer of FedEx Corporation, and also serves as Co-President and Co-CEO of FedEx Services. His expertise in technology and corporate leadership is a key asset for the company's strategic direction.

Yes, the Board of Directors has determined that Mr. Carter is an independent director. This determination was made after considering the recommendation of the Board's Governance Committee and in accordance with the New York Stock Exchange listing standards and Quest Diagnostics' own Corporate Governance Guidelines.

Yes, Mr. Carter will be compensated as a non-employee director. His compensation will follow the company's established practices for directors who are not full-time employees of Quest Diagnostics.

At the time of this filing, Mr. Carter's membership on any specific Board committees has not yet been determined.